NC
KYTX icon

nVerses Capital’s Kyverna Therapeutics KYTX Stock Holding History

nVerses Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-600
Closed -$2.93K – 928
2024
Q3 		$2.93K Buy
+600
New +$4.63K ﹤0.01% 947

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

nVerses Capital's KYTX Position: Q4 2024 in Review

nVerses Capital sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 600 shares — an estimated $2.93K sold.

nVerses Capital first reported a position in KYTX in Q3 2024 and held it in 1 quarter. The position peaked at $2.93K in Q3 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • nVerses Capital reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 600 Kyverna Therapeutics shares in Q4 2024, an estimated $2.93K.
  • nVerses Capital first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Kyverna Therapeutics position peaked at $2.93K in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.